Axis Direct's research report on Ipca Laboratories
IPCA’s Q3 EBITDA at Rs 1.02 bn (up 30% YoY) was in line with our estimate, on account of strong gross margin expansion. However, Q3 PAT was 25% below estimate due to higher tax expense. Domestic formulation witnessed 9% YoY growth, moderately impacted by demonetization.
Outlook
We cut FY17/18/19F EPS by 13%/4%/3% owing to higher tax outgo with revised TP of Rs 580 (18x Dec’18) vs. Rs 600 (18x Dec’18). Maintain BUY given operating leverage play.
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
